H.C. Wainwright Thinks Atreca’s Stock is Going to Recover
12 May 2022 - 08:16PM
TipRanks
In a report released today, Joseph Pantginis from H.C. Wainwright
reiterated a Buy rating on Atreca (BCEL – Research Report), with a
price target of $25.00. The company's shares closed last Wednesday
at $1.61, close to its 52-week low of $1.56. According to
TipRanks.com, Pantginis has currently 0 stars on a ranking scale of
0-5 stars, with an average return of -33.5% and a 12.1% success
rate. Pantginis covers the Healthcare sector, focusing on stocks
such as Applied Genetic Technologies, Lineage Cell Therapeutics,
and Actinium Pharmaceuticals. Atreca has an analyst consensus of
Strong Buy, with a price target consensus of $18.00.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-atrecas-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Apr 2023 to May 2023
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From May 2022 to May 2023
